Key result
Takotsubo cardiomyopathy survivors had a 1-month readmission rate of 10.3%, predominantly for noncardiac causes, with an associated annual national cost impact of ≈$112 million.
Population
5997 patients with primary admission for takotsubo cardiomyopathy identified from the National Readmissions…
Design
Cohort
Follow-up
6 months
Authors
Loading...
Alerts to substantial early readmission burden after Takotsubo cardiomyopathy; leaves open optimal strategies to mitigate noncardiac causes.
Observational (n=5,997)
Yes
One-month readmission after takotsubo cardiomyopathy occurs in 10.3% of patients, predominantly for noncardiac causes, and carries a significant economic burden.
Shah et al. (2018) conducted an observational in Takotsubo cardiomyopathy (n=5,997). Takotsubo cardiomyopathy survivors had a 1-month readmission rate of 10.3%, predominantly for noncardiac causes, with an associated annual national cost impact of ≈$112 million.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: